Plasma N-glycans in colorectal cancer risk

Margaret Doherty, Evropi Theodoratou, Ian Walsh, Barbara Adamczyk, Henning Stöckmann, Felix Agakov, Maria Timofeeva, Irena Trbojević-Akmačić, Frano Vučković, Fergal Duffy, Ciara A. McManus, Susan M. Farrington, Malcolm G. Dunlop, Markus Perola, Gordan Lauc, Harry Campbell, Pauline M. Rudd

Research output: Contribution to journalArticlepeer-review

60 Citations (Scopus)

Abstract

Aberrant glycosylation has been associated with a number of diseases including cancer. Our aim was to elucidate changes in whole plasma N-glycosylation between colorectal cancer (CRC) cases and controls in one of the largest cohorts of its kind. A set of 633 CRC patients and 478 age and gender matched controls was analysed. Additionally, patients were stratified into four CRC stages. Moreover, N-glycan analysis was carried out in plasma of 40 patients collected prior to the initial diagnosis of CRC. Statistically significant differences were observed in the plasma N-glycome at all stages of CRC, this included a highly significant decrease in relation to the core fucosylated bi-antennary glycans F(6)A2G2 and F(6)A2G2S(6)1 (P < 0.0009). Stage 1 showed a unique biomarker signature compared to stages 2, 3 and 4. There were indications that at risk groups could be identified from the glycome (retrospective AUC = 0.77 and prospective AUC = 0.65). N-glycome biomarkers related to the pathogenic progress of the disease would be a considerable asset in a clinical setting and it could enable novel therapeutics to be developed to target the disease in patients at risk of progression.

Original languageEnglish
Article number8655
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - 1 Dec 2018

Fingerprint

Dive into the research topics of 'Plasma N-glycans in colorectal cancer risk'. Together they form a unique fingerprint.

Cite this